Shares of Vaxcyte Inc. (PCVX) have fallen roughly 64% from their 52-week high of $116, recorded last November, to around $42. As the company nears a significant near-term milestone for one of its drug candidates, could this spark a recovery in its stock and attract renewed investor interest?
The clinical-stage vaccine innovation company is focused on developing a pipeline of pneumococcal conjugate vaccine (PCV) candidates under clinical development, along with preclinical-stage programs targeting Group A Streptococcus and Shigella.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com